Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Medical Genetics
Published in: BMC Medical Genetics 1/2009

Open Access 01-12-2009 | Research article

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population

Authors: William Kudzi, Alexander NO Dodoo, Jeremy J Mills

Published in: BMC Medical Genetics | Issue 1/2009

Login to get access

Abstract

Background

Genetic influences on drug efficacy and tolerability are now widely known. Pharmacogenetics has thus become an expanding field with great potential for improving drug efficacy and reducing toxicity. Many pharmacologically-relevant polymorphisms do show variability among different populations. Knowledge of allelic frequency distribution within specified populations can be useful in explaining therapeutic failures, identifying potential risk groups for adverse drug reactions (ADRs) and optimising doses for therapeutic efficacy. We sought to determine the prevalence of clinically relevant Cytochrome P450 (CYP) 2C8, CYP2C9, and CYP2C19 variants in Ghanaians. We compared the data with other ethnic groups and further investigated intra country differences within the Ghanaian population to determine its value to pharmacogenetics studies.

Methods

RFLP assays were used to genotype CYP2C8 (*2, *3, *4) variant alleles in 204 unrelated Ghanaians. CYP2C9*2 and CYP2C19 (*2 and *3) variants were determined by single-tube tetra-primer assays while CYP2C9 (*3, *4, *5 and *11) variants were assessed by direct sequencing.

Results

Allelic frequencies were obtained for CYP2C8*2 (17%), CYP2C8*3 (0%), CYP2C8*4 (0%), CYP2C9*2 (0%), CYP2C9*3 (0%), CYP2C9*4 (0%), CYP2C9*5 (0%), CYP2C9*11 (2%), CYP2C19*2 (6%) and CYP2C19*3 (0%).

Conclusion

Allele frequency distributions for CYP2C8, CYP2C9 and CYP2C19 among the Ghanaian population are comparable to other African ethnic groups but significantly differ from Caucasian and Asian populations. Variant allele frequencies for CYP2C9 and CYP2C19 are reported for the first time among indigenous Ghanaian population.
Literature
1.
Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG: Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics. 2002, 12 (2): 121-132. 10.1097/00008571-200203000-00006.CrossRefPubMed
2.
Garcia-Martin E, Martinez C, Ladero JM, Agundez JA: Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther. 2006, 10 (1): 29-40.CrossRefPubMed
3.
Goldstein JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001, 52 (4): 349-355. 10.1046/j.0306-5251.2001.01499.x.CrossRefPubMedPubMedCentral
4.
Pirmohamed M, Park BK: Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology. 2003, 192 (1): 23-32. 10.1016/S0300-483X(03)00247-6.CrossRefPubMed
5.
Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrere N, Maurel P: Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001, 29 (3): 242-251.PubMed
6.
Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001, 11 (7): 597-607. 10.1097/00008571-200110000-00006.CrossRefPubMed
7.
Yasar U, Bennet AM, Eliasson E, Lundgren S, Wiman B, De Faire U, Rane A: Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics. 2003, 13 (12): 715-720. 10.1097/00008571-200312000-00002.CrossRefPubMed
8.
Miners JO, Birkett DJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998, 45 (6): 525-538. 10.1046/j.1365-2125.1998.00721.x.CrossRefPubMedPubMedCentral
9.
Xie HG, Prasad HC, Kim RB, Stein CM: CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002, 54 (10): 1257-1270. 10.1016/S0169-409X(02)00076-5.CrossRefPubMed
10.
Martinez C, Blanco G, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, Diaz-Rubio M, Agundez JA: Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004, 141 (2): 205-208. 10.1038/sj.bjp.0705623.CrossRefPubMedPubMedCentral
11.
Sanderson S, Emery J, Higgins J: CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med. 2005, 7 (2): 97-104. 10.1002/ajmg.a.30391.CrossRefPubMed
12.
Weide van der J, Steijns LS, van Weelden MJ, de Haan K: The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics. 2001, 11 (4): 287-291. 10.1097/00008571-200106000-00002.CrossRefPubMed
13.
14.
Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, et al: CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol. 2002, 64 (11): 1579-1589. 10.1016/S0006-2952(02)01354-0.CrossRefPubMed
15.
Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y: Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol. 2003, 56 (6): 653-657. 10.1046/j.1365-2125.2003.01937.x.CrossRefPubMedPubMedCentral
16.
Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E: Two single-tube tetra-primer assays to detect the CYP2C19*2 and *3 alleles of S-mephenytoin hydroxylase. Clin Chem. 2001, 47 (4): 772-774.PubMed
17.
Rower SBU, Weise A, Lambertz U, Frost T, Otchwemah RN, Pfutzner A, Mockkenhaupt F: High prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Tropical Medicine and International Health. 2005, 10 (12): 1271-1273.CrossRefPubMed
18.
Dreisbach AW, Japa S, Sigel A, Parenti MB, Hess AE, Srinouanprachanh SL, Rettie AE, Kim H, Farin FM, Hamm LL, et al: The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens. 2005, 18 (10): 1276-1281. 10.1016/j.amjhyper.2005.04.019.CrossRefPubMed
19.
Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL: Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007, 82 (2): 197-203. 10.1038/sj.clpt.6100122.CrossRefPubMed
20.
Cavaco I, Stromberg-Norklit J, Kaneko A, Msellem MI, Dahoma M, Ribeiro VL, Bjorkman A, Gil JP: CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol. 2005, 61 (1): 15-18. 10.1007/s00228-004-0871-8.CrossRefPubMed
21.
Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, Rane A: Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun. 2002, 299 (1): 25-28. 10.1016/S0006-291X(02)02592-5.CrossRefPubMed
22.
Weise A, Grundler S, Zaumsegel D, Klotzek M, Grondahl B, Forst T, Pfutzner A: Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping. Clin Lab. 2004, 50 (3-4): 141-148.PubMed
23.
Rower S, Bienzle U, Weise A, Lambertz U, Forst T, Otchwemah RN, Pfutzner A, Mockenhaupt FP: Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop Med Int Health. 2005, 10 (12): 1271-1273.CrossRefPubMed
24.
Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M: Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol. 2001, 52 (4): 447-450. 10.1046/j.0306-5251.2001.01460.x.CrossRefPubMedPubMedCentral
25.
Crespi CL, Miller VP: The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics. 1997, 7 (3): 203-210. 10.1097/00008571-199706000-00005.CrossRefPubMed
26.
Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K: CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics. 2000, 10 (2): 95-104. 10.1097/00008571-200003000-00001.CrossRefPubMed
27.
Schwarz UI: Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest. 2003, 33 (Suppl 2): 23-30. 10.1046/j.1365-2362.33.s2.6.x.CrossRefPubMed
28.
Lee CR, Goldstein JA, Pieper JA: Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002, 12 (3): 251-263. 10.1097/00008571-200204000-00010.CrossRefPubMed
29.
Shorr RI, Ray WA, Daugherty JR, Griffin MR: Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996, 44 (7): 751-755.CrossRefPubMed
30.
White RH, Beyth RJ, Zhou H, Romano PS: Major bleeding after hospitalization for deep-venous thrombosis. Am J Med. 1999, 107 (5): 414-424. 10.1016/S0002-9343(99)00267-3.CrossRefPubMed
31.
De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994, 46 (4): 594-598.PubMed
32.
de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994, 269 (22): 15419-15422.PubMed
33.
Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA: Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997, 7 (1): 59-64. 10.1097/00008571-199702000-00008.CrossRefPubMed
34.
Dandara C, Masimirembwa CM, Magimba A, Sayi J, Kaaya S, Sommers DK, Snyman JR, Hasler JA: Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol. 2001, 57 (1): 11-17. 10.1007/s002280100282.CrossRefPubMed
35.
Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, Frotschl R, Kopke K, Gerloff T, Chernov JN, Roots I: Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol. 2003, 59 (4): 303-312. 10.1007/s00228-003-0606-2.CrossRefPubMed
36.
Goldstein JA, de Morais SM: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994, 4 (6): 285-299. 10.1097/00008571-199412000-00001.CrossRefPubMed
37.
Fukushima-Uesaka H, Saito Y, Maekawa K, Ozawa S, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, et al: Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab Pharmacokinet. 2005, 20 (4): 300-307. 10.2133/dmpk.20.300.CrossRefPubMed
38.
Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics. 2003, 13 (2): 89-95. 10.1097/00008571-200302000-00005.CrossRefPubMed
39.
Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Muller M, Hiemke C, Freymann N, Zobel A, Maier W, Rao ML: Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol. 2004, 60 (5): 329-336. 10.1007/s00228-004-0766-8.CrossRefPubMed
40.
Einarson TR: Drug-related hospital admissions. Ann Pharmacother. 1993, 27 (7-8): 832-840.PubMed
41.
Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama. 1998, 279 (15): 1200-1205. 10.1001/jama.279.15.1200.CrossRefPubMed
42.
Bosch TM, Doodeman VD, Smits PH, Meijerman I, Schellens JH, Beijnen JH: Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. Mol Diagn Ther. 2006, 10 (3): 175-185.CrossRefPubMed
43.
Adithan C, Gerard N, Vasu S, Rosemary J, Shashindran CH, Krishnamoorthy R: Allele and genotype frequency of CYP2C19 in a Tamilian population. Br J Clin Pharmacol. 2003, 56 (3): 331-333. 10.1046/j.1365-2125.2003.01883.x.CrossRefPubMedPubMedCentral
Metadata
Title
Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
Authors
William Kudzi
Alexander NO Dodoo
Jeremy J Mills
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Medical Genetics / Issue 1/2009
Electronic ISSN: 1471-2350
DOI
https://doi.org/10.1186/1471-2350-10-124

Other articles of this Issue 1/2009

BMC Medical Genetics 1/2009 Go to the issue

Research article

Variation in cytokine genes can contribute to severity of acetabular osteolysis and risk for revision in patients with ABG 1 total hip arthroplasty: a genetic association study

Research article

An investigation of ribosomal protein L10 gene in autism spectrum disorders

Research article

Single nucleotide polymorphisms in obesity-related genes and all-cause and cause-specific mortality: a prospective cohort study

Research article

The role of CACNA1Sin predisposition to malignant hyperthermia

Research article

Two-stage case-control association study of dopamine-related genes and migraine

Research article

Search for cardiac calcium cycling gene mutations in familial ventricular arrhythmias resembling catecholaminergic polymorphic ventricular tachycardia